<DOC>
	<DOCNO>NCT00761384</DOCNO>
	<brief_summary>90Y-ibritumomab give stem cell support , base absorbed dose escalation liver . Absorbed dose escalation start 12 Gy cap 36 Gy liver .</brief_summary>
	<brief_title>High Dose , Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells ( PBSC ) Support B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Written inform concent Age least 18 year WHO Performance status 03 Histologically verify Bcell lymphoma Diffuse large Bcell lymphoma follicular grade III , fail anthracycline contain regimen patient find suitable second line chemotherapy consolidate high dose chemotherapy ( HDCT ) stem cell support radiotherapy Transformed Bcell lymphoma , fail first line therapy suitable high dose chemotherapy ( HDCT ) history HDCT stem cell support Follicular lymphoma grade II I , indolent lymphoma must fail second line treatment . One treatment must contain chemotherapy rituximab , latter either together chemotherapy maintenance . The lymphoma must require treatment , Mantle cell lymphoma , fail first line treatment , treatment require Measurable disease tumor burden must acceptable accord investigator Radiological study must perform unilateral bone marrow biopsy within 4 week start treatment Bone marrow reserve likely give harvest least 2x10 6 peripheral CD34+ stemcells existence harvest correspond central harvest Total bilirubin exceed 40 micromole/L A GFR measure Cystatin C 50 ml/min HIV , Hepatitis B C status know Life expectancy least 3 month . Known clinical evidence CNS involvement Bone marrow involvement harvest measure biopsy flow cytometry Subjects prior radiation field include equal 25 % red marrow , liver lung kidney Prior chemotherapy radiotherapy within 4 week Subjects pregnant nursing Pulmonary involvement , negligible discretion investigator Liver involvement lymphoma History hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>B-cell lymphoma</keyword>
	<keyword>Refractory</keyword>
	<keyword>Recurrent</keyword>
	<keyword>90Y-ibritumomab</keyword>
	<keyword>Stem cell support</keyword>
	<keyword>Dosimetry study</keyword>
</DOC>